Cancer Biological Therapy Market By Type of Therapy (Monoclonal Antibodies, Cancer Vaccines), Cancer Type (Breast Cancer, Lung Cancer), End-User (Hospitals Cancer Treatment Centers), & Region for 2024-2031

Cancer Biological Therapy Market Valuation – 2024-2031

Increasing global prevalence of cancer boosts demand for innovative treatment options is propelling the adoption of cancer biological therapy. The shift towards personalized medicine, focusing on treatments tailored to individual genetic profiles is driving the market size surpass USD 93.74 Billion valued in 2024 to reach a valuation of around USD 153.35 Billion by 2031.

In addition to this, clinical success and improved patient outcomes with biological therapies are spurring up the adoption of cancer biological therapy. Increased government funding and favorable policies for cancer research and treatment is enabling the market to grow at a CAGR of 7% from 2024 to 2031.

Cancer Biological Therapy MarketDefinition/ Overview

Cancer biological therapy, also known as biotherapy or immunotherapy, involves the use of living organisms, substances derived from living organisms, or synthetic versions of such substances to treat cancer. These therapies work by enhancing the body’s natural defenses to fight cancer or by targeting specific molecules involved in cancer growth and progression. Examples of biological therapies include monoclonal antibodies, cancer vaccines, and cell-based therapies.

Cancer biological therapies are used to treat various types of cancer, often in combination with other treatments such as chemotherapy, radiation, and surgery. They are particularly effective in targeting specific cancer cells while minimizing damage to normal cells. Monoclonal antibodies can be used to block cancer cell growth, mark cancer cells for destruction by the immune system, or deliver radiation or chemotherapy directly to cancer cells. Cancer vaccines aim to stimulate the immune system to attack cancer cells, and cell-based therapies, such as CAR T-cell therapy, involve modifying a patient’s own immune cells to target cancer more effectively.

How will Rising Global Cancer Prevalence Increase Adoption of Cancer Biological Therapy?

The rising global cancer prevalence is a primary driver of the cancer biological therapy market. According to the World Health Organization, cancer cases are projected to increase by 60% by 2040 from 2020 levels. The U.S. National Cancer Institute reported that approximately 39.5% of people will be diagnosed with cancer at some point in their lives. This increasing burden has led to greater demand for effective and targeted treatments like biological therapies. In response to this trend, Merck announced in February 2024 the expansion of its immuno-oncology pipeline, focusing on novel checkpoint inhibitors. Similarly, Roche introduced a new personalized cancer vaccine platform in April 2024, combining mRNA technology with their established biological therapies.

Advancements in biotechnology and a deeper understanding of cancer biology are fueling innovation in biological therapies. The U.S. Food and Drug Administration (FDA) approved 18 new biological therapies for cancer treatment between 2020 and 2024. A report from the European Medicines Agency showed a 35% increase in biological therapy clinical trials for cancer from 2021 to 2023. These developments are leading to more effective and targeted treatments with fewer side effects. In March 2024, Bristol Myers Squibb unveiled a groundbreaking CAR-T cell therapy for solid tumors, expanding the application of this biological approach. Novartis announced in May 2024 the successful phase III trial results for a bispecific antibody targeting multiple myeloma, demonstrating significant improvements in progression-free survival.

Will Lack of Accessibility and Availability of Cancer Biological Therapy Restrain Its Application?

One of the significant restraints in the cancer biological therapy market is the high cost associated with these treatments. Biological therapies, such as monoclonal antibodies and CAR T-cell therapy, are often expensive to develop, produce, and administer. The costs include not only the complex manufacturing processes but also the need for specialized handling and administration by trained healthcare professionals. This financial burden can limit accessibility for many patients, particularly in low- and middle-income countries, and poses a challenge for healthcare systems and insurance providers in managing the high expenses associated with these advanced treatments.

Lack of accessibility and availability of cancer biological therapies are also major challenges. Due to the specialized nature of these treatments, they may not be widely available in all regions, particularly in remote or underdeveloped areas. The need for sophisticated healthcare infrastructure, including specialized facilities and trained personnel, further restricts the widespread adoption of biological therapies. Additionally, regulatory approvals and market entry barriers can delay the availability of new treatments, impacting the timely delivery of these therapies to patients in need.

Cancer biological therapies can cause significant adverse effects and unintended immune responses, such as cytokine release syndrome (CRS). These side effects require careful monitoring and complicate treatment protocols, making it challenging for clinicians to balance efficacy and safety. Severe side effects can deter patients and create additional challenges for healthcare providers in managing biological treatments.

Category-Wise Acumens

Will Rise in Adoption of Monoclonal Antibodies (mAbs) Drive Cancer Biological Therapy Market?

Monoclonal antibodies (mAbs) is emerging as the leading segment in the cancer biological therapy market. According to the FDA, mAbs accounted for 35% of all cancer biological therapy approvals between 2020 and 2024. The National Cancer Institute reported that mAb therapies were used in 40% of cancer treatment regimens in the U.S. by 2023. This dominance is attributed to their high specificity and efficacy in targeting cancer cells. In February 2024, Roche announced the successful phase III trial results for a novel bispecific antibody targeting both HER2 and PD-1 in breast cancer patients. Similarly, Merck launched an advanced mAb therapy in April 2024, demonstrating improved overall survival rates in lung cancer patients.

The versatility of monoclonal antibodies in combination therapies is driving their market growth. The American Society of Clinical Oncology reported a 28% increase in clinical trials involving mAb combination therapies from 2021 to 2023. The European Medicines Agency approved 15 new mAb-based combination treatments between 2020 and 2024. This trend reflects the growing recognition of mAbs’ potential to enhance treatment efficacy when used with other therapies. In March 2024, Bristol Myers Squibb introduced a groundbreaking triple combination therapy featuring two mAbs and a small molecule inhibitor for advanced melanoma. AstraZeneca partnered with a leading biotech firm in May 2024 to develop next-generation antibody-drug conjugates for multiple cancer types.

Which Factors Enhance the Use of Cancer Biological Therapy in Hospitals?

Hospitals is expected to emerge as the primary distribution channel for cancer biological therapies. According to the American Hospital Association, 72% of all cancer biological treatments were administered in hospital settings in 2023. The Centers for Medicare & Medicaid Services reported that hospital outpatient departments accounted for 65% of cancer biological therapy claims in 2024. This dominance is attributed to the complex nature of these treatments and the need for specialized care. In February 2024, the Mayo Clinic announced the expansion of its cancer biological therapy units across all major branches. Similarly, Cleveland Clinic partnered with Roche in April 2024 to establish advanced biological therapy infusion centers in its hospitals.

The rise of hospital-based cancer centers is fueling the growth of biological therapy administration. The National Cancer Institute reported a 30% increase in NCI-designated cancer centers from 2020 to 2024. A survey by the American Society of Clinical Oncology found that 80% of oncologists preferred hospital settings for administering complex biological therapies in 2023. This trend reflects the need for comprehensive care and immediate access to emergency services. In March 2024, MD Anderson Cancer Center unveiled a state-of-the-art biological therapy wing, featuring personalized treatment suites. NewYork-Presbyterian Hospital launched an integrated immunotherapy program in May 2024, centralizing all biological therapy services.

Gain Access into Cancer Biological Therapy Market Report Methodology

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Cancer Biological Therapy Market?

North America leads the global cancer biological therapy market due to advanced healthcare infrastructure and high adoption rates. According to the National Cancer Institute, biological therapies accounted for 35% of all cancer treatments in the U.S. by 2023. The Canadian Cancer Society reported a 28% increase in biological therapy usage from 2020 to 2024. This dominance is fueled by substantial research funding and a robust biotechnology industry. In February 2024, the U.S. FDA approved a record number of 12 new cancer biological therapies. Merck, a key player, announced in April 2024 a USD 2 Billion investment to expand its biological therapy production facilities across North America.

The region’s strong reimbursement policies and insurance coverage drive market growth. The Centers for Medicare & Medicaid Services reported that spending on cancer biological therapies increased by 40% between 2020 and 2024. A study by the American Cancer Society found that 85% of cancer patients had access to biological therapies through insurance in 2023. This financial support enhances patient access to advanced treatments. In March 2024, UnitedHealth Group expanded its coverage for CAR-T cell therapies, benefiting thousands of cancer patients. Roche partnered with major U.S. insurers in May 2024 to introduce innovative payment models for its portfolio of biological cancer treatments.

North America’s leadership in clinical trials and personalized medicine boosts its market position. The NIH Clinical Trials database showed that 60% of global cancer biological therapy trials were conducted in North America in 2023. Health Canada reported a 25% increase in precision medicine approvals for cancer from 2021 to 2024. This focus on innovation drives the development of more effective therapies. In January 2024, Gilead Sciences launched a groundbreaking personalized neoantigen therapy in the U.S. market. Bristol Myers Squibb announced in June 2024 the successful completion of the largest pan-cancer immunotherapy trial to date, conducted across multiple North American centers.

Will Increasing Cancer Prevalence Enhance Adoption of Cancer Biological Therapy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the cancer biological therapy market due to increasing cancer prevalence and improving healthcare infrastructure. According to the World Health Organization, cancer cases in Asia are projected to increase by 35% from 2020 to 2030. China’s National Cancer Center reported a 25% rise in biological therapy adoption from 2021 to 2023. This growth is driven by government initiatives and rising healthcare expenditure. In February 2024, the Indian Council of Medical Research announced a $500 million investment in cancer biological therapy research. Japan’s Ministry of Health approved 8 new cancer biological therapies in 2023, marking a 40% increase from the previous year.

Expansion of local biopharmaceutical companies and partnerships with global players are fueling market growth. The China National Medical Products Administration reported a 30% increase in domestic cancer biological therapy approvals between 2020 and 2024. South Korea’s Ministry of Food and Drug Safety noted a 45% growth in biological therapy clinical trials from 2022 to 2024. These developments are enhancing the region’s capacity for advanced cancer treatments. In March 2024, BeiGene partnered with Novartis to expand its biological therapy portfolio across Asia. Singapore-based Tessa Therapeutics raised $200 million in April 2024 to advance its CAR-T cell therapy pipeline for solid tumors. At the forefront, the availability of local vendors offering competitive pricing cloud-based solutions increase the accessibility and availability of Cancer Biological Therapy to businesses of all sizes, driving wider adoption.

Competitive Landscape

The cancer biological therapy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the cancer biological therapy market include

• Bristol-Myers Squibb
• Merck & Co., Inc.
• Roche Holding AG
• Novartis International AG
• AstraZeneca
• Pfizer, Inc.
• Amgen, Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Sanofi S.A.
• Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
• Gilead Sciences, Inc.
• AbbVie, Inc.
• Biogen, Inc.
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals, Inc.
• Seagen, Inc.
• Incyte Corporation
• Adaptimmune Therapeutics plc.

Latest Developments

• In September 2023, Novartis received FDA approval for a next-generation targeted therapy for breast cancer, marking a significant advancement in precision medicine and biological treatments.
• In August 2023, AstraZeneca announced a collaboration with a leading research institute to explore the use of gene editing technologies in developing new biological therapies for lung cancer.

Report Scope

Cancer Biological Therapy Market, By Category

Type of Therapy

• Monoclonal Antibodies
• Cancer Vaccines
• Cytokines
• Gene Therapy
• Targeted Therapy

Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma

End-User

• Hospitals
• Cancer Treatment Centers
• Clinics
• Ambulatory Surgical Centers

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.